Abstract
Most monoclonal antibodies in clinical trials are owned by small biotech companies. But with blockbuster-sized revenues and approval rates higher than those for small-molecule drugs, that all may be set to change.
MeSH terms
-
Animals
-
Antibodies, Monoclonal / chemistry
-
Antibodies, Monoclonal / therapeutic use*
-
Biotechnology / methods
-
Biotechnology / trends
-
Chemistry, Pharmaceutical / trends
-
Clinical Trials as Topic
-
Drug Approval
-
Drug Industry / trends
-
Humans
-
Hybridomas / metabolism
-
Immunotherapy / methods*
-
Neoplasms / therapy
-
United States
-
United States Food and Drug Administration